News Articles

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic... INGELHEIM, Germany -Tuesday 19 October 2021  

(BUSINESS WIRE) -- Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium (GTC, consisting of researchers from Imperial College London and the Universities of Oxford and Edinburgh) and Oxford Biomedica (OXB), announced today that Boehringer Ingelheim has exercised its...

Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel... -Tuesday 21 September 2021  

(BUSINESS WIRE) -- Boehringer Ingelheim today announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology research to develop the next generation of precision medicines designed to revolutionize cancer...

Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart... -Saturday 28 August 2021

(BUSINESS WIRE) -- Full results from the landmark EMPEROR-Preserved Phase III trial demonstrated that empagliflozin showed an impressive 21 percent relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure in adults with heart failure...

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development -Tuesday 3 August 2021

Breakthrough results in the treatment of a type of heart failure, which is extremely difficult to manage Strong progress in mental health pipeline Good business performance in all areas, despite ongoing impact of COVID-19 (BUSINESS WIRE)-- In the first half of 2021, Boehringer...

Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure... -Tuesday 6 July 2021  

- The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction with empagliflozin for the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction (HFpEF) - HFpEF has...

Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4... -Monday 28 June 2021  

- Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kidney injury requiring dialysis, compared to DPP-4 inhibitors - This analysis, which includes European...

Jardiance® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection... -Monday 21 June 2021  

- This new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization for heart failure with reduced ejection fraction in adults with or without diabetes and an eGFR of...

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity -Tuesday 13 April 2021  

(BUSINESS WIRE) -- Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) announced the initiation of two Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH). The compound...

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19 -Wednesday 24 March 2021  

(BUSINESS WIRE) -- Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines and therapies for diseases for which no satisfactory treatments are available. In particular, efforts to research potential COVID-19 related therapies were...

Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity -Monday 1 March 2021  

The research agreement builds upon the successful relationship between Boehringer Ingelheim and Gubra and expands Boehringer Ingelheim’s research into approaches with first in class potential for the treatment of obesity Obesity is a complex cardiometabolic disease with growing global...

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D -Monday 11 January 2021

● Quantum computing offers the potential to significantly accelerate and optimize the discovery of future new medicines for patients ● Scientists from both companies will be breaking new ground in the application of quantum computing to molecular dynamics simulations ● Boehringer...

Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa® (dabigatran etexilate) for the... -Monday 16 November 2020

No approved therapy for the treatment and prevention of venous thromboembolic events in children until now Current standard of care often associated with frequent monitoring of anticoagulation or daily injections1 Positive opinion is based on a dedicated clinical pediatric program for...

Boehringer Ingelheim invests to further develop the pet care market in China -Tuesday 29 September 2020

(BUSINESS WIRE)-- Boehringer Ingelheim has acquired an equity stake in China-based New Ruipeng Group (NRP Group). NRP Group is a fast-growing business that offers veterinary care, e-commerce and many other services to pet owners and the broader animal health market across China. “Improving...

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25... -Saturday 29 August 2020  

(BUSINESS WIRE)-- Full results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, showed that empagliflozin was associated with a significant 25 percent relative risk reduction in the primary endpoint of time to...

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus... -Tuesday 18 August 2020  

CARE (Corona Accelerated R&D in Europe), supported by Europe’s Innovative Medicines Initiative (IMI), is the largest undertaking of its kind dedicated to discovering and developing urgently needed treatment options for COVID-19. The initiative is committed to a long-term...

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in... -Thursday 30 July 2020  

(BUSINESS WIRE)-- Positive top-line results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, were announced today by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY). EMPEROR-Reduced met its primary...

Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health -Monday 27 July 2020

(BUSINESS WIRE)-- Boehringer Ingelheim, a market leader in animal health, has acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company. GST is dedicated to the research, development and production of evidence-based, regenerative medicines (stem cell therapies) used to...

European Commission approves third nintedanib indication in pulmonary fibrosis1 -Wednesday 15 July 2020  

The approval is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1 The decision is based on the results of the INBUILD® trial, the first study to evaluate patients with a...

Perceived burden of disease is greater in younger people living with COPD, global survey reveals -Thursday 9 July 2020  

(BUSINESS WIRE) -- Results of a global survey of 1,375 adults aged at least 45 years old and living with Chronic Obstructive Pulmonary Disease (COPD) in 11 countries have been published in COPD: Journal of Chronic Obstructive Pulmonary Disease.1 Findings indicate that COPD has a substantial...

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology... -Thursday 14 May 2020  

(BUSINESS WIRE)-- Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the...